HomepageMedicineMerck Obtains Global License for Hansoh’s HS-10535 Medicine Merck Obtains Global License for Hansoh’s HS-10535 admin Posted on December 23, 2024 The molecule is an investigational pre-clinical oral GLP-1 receptor agonist. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostAsk Dr. Paola – Monday December 23, 2024 Next PostWill There Ever Be Real Size Diversity in Fashion? You Might Also Like Medicine Gilead Discontinuing Development of Magrolimab in Hematologic Cancers Following Full Clinical Hold by FDA for Increased Risk of Death admin February 8, 2024 Medicine Pharma Pulse 12/20/24: Trends in Enterprise Value Growth and Value-to-Sales Ratios, PPF, Its Risk Factors & more admin December 23, 2024 Medicine Merck, Moderna Launch Phase III Trial of V940 in Combination with Keytruda for Resectable Non-Small Cell Lung Cancer admin October 29, 2024 Medicine AstraZeneca VP, Head of Medical Affairs, US Oncology, Discusses the Impact of PARP Inhibitors on Cancer Treatment admin August 13, 2024
Medicine Gilead Discontinuing Development of Magrolimab in Hematologic Cancers Following Full Clinical Hold by FDA for Increased Risk of Death admin February 8, 2024
Medicine Pharma Pulse 12/20/24: Trends in Enterprise Value Growth and Value-to-Sales Ratios, PPF, Its Risk Factors & more admin December 23, 2024
Medicine Merck, Moderna Launch Phase III Trial of V940 in Combination with Keytruda for Resectable Non-Small Cell Lung Cancer admin October 29, 2024
Medicine AstraZeneca VP, Head of Medical Affairs, US Oncology, Discusses the Impact of PARP Inhibitors on Cancer Treatment admin August 13, 2024